结构治疗学因口服GLP-1的中期数据而上涨

2026-03-17 00:27

Structure Therapeutics (GPCR) is ~8% in Monday trading after reporting promising topline phase 2 data on its oral GLP-1 receptor agonist, aleniglipron, for obesity.
Data was from the 44-week ACCESS II study as well as interim data from the ongoing body composition study and the ACCESS open-label extension study.
In ACCESS II, aleniglipron given once daily achieved meaningful placebo-adjusted mean weight loss of 16.3% at the 180 mg dose and 16% at the 240 mg dose at 44 weeks.
In the open-label extension study, aleniglipron led to continued weight loss up to 16.2% at the 120 mg dose at 56 weeks. Also, there was no sign of a weight loss plateau in either study.
Structure anticipates moving into phase 3 in the second half of the year.

More on Structure Therapeutics